Retrospective comparison between CHOP-PVP and CHOP protocols for non-Hodgkin's lymphoma.
- Author:
Huizhu GAN
1
;
Fengchun ZHANG
;
Yumei LIN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Child; Cyclophosphamide; therapeutic use; Doxorubicin; therapeutic use; Female; Humans; Lymphoma, Non-Hodgkin; drug therapy; Male; Middle Aged; Prednisone; therapeutic use; Retrospective Studies; Survival Rate; Treatment Outcome; Vincristine; therapeutic use
- From: Chinese Journal of Oncology 2002;24(4):397-399
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo compare the therapeutic effects between CHOP-PVP and CHOP protocols for non-Hodgkin's lymphoma (NHL).
METHODSOf 79 NHL patients, 40 received CHOP-PVP and 39 received CHOP protocol. Kaplan-Meier method was used for survival rate and Cox regression model for prognostic factors.
RESULTSThe complete remission rate and overall response rate were 57.5% (23/40) and 87.5% (35/40) in CHOP-PVP group and they were 33.3% (13/39) and 69.2% (27/39) in CHOP group. There was a significant difference (P < 0.05) in the complete remission rate and overall response rate between the two groups. The main toxicity was myelosuppression. The leukocytopenia rate was 82.5% in CHOP-PVP group and 71.8% in CHOP group (P > 0.05) with no fatality in either group.
CONCLUSIONCHOP-PVP protocol may be more effective for non-Hodgkin's lymphoma than CHOP protocol without increasing toxicity.
